In a recent meta-analysis of randomized and placebo-controlled trials of innovative therapies in MG with available efficacy data, we concluded that anti-complement and anti-FcRn treatments proved to be effective in gMG patients while rituximab did not show any significant effect on the MG-ADL score [9]. Here, FCGRT is linked to myasthenia gravis.